The FDA announced on May 6, 2022, that Sun Pharmaceutical Industries Inc. voluntarily recalled medroxyPROGESTERone Acetate Injectable Suspension due to a lack of assurance of sterility. The recall affects 57,997 syringes distributed nationwide.
How to tell if you have it
- Brand: Sun Pharmaceutical
- Product: medroxyPROGESTERone Acetate Injectable Suspension, USP, 1 mL Prefilled Syringe, 150 mg/mL
- NDC: 16714-999-01
- Lot codes: HAC1289A (Exp 06/2023), JKX2679A (Exp 06/2022), JKX3762A (Exp 08/2022), HAC0164A (Exp 06/2023)
- Quantity: 57,997 syringes
The hazard
The recall was initiated because the firm could not assure sterility of the product. The FDA classified this as a Class II recall.
Context
GovInfoNow's records show Sun Pharmaceutical Industries Inc. has 93 other recalls on record since May 21, 2013. Other recent recalls include a September 14, 2026 Nystatin Cream recall for failed stability specifications and an August 3, 2026 Carbamazepine Tablets recall for black spots from burnt ingredients. Similar product recalls in June 2026 involved Reliance Pemetrexed Injection sterility risks and a February 26, 2026 New Life Pharma Semaglutide Injections recall for lack of sterility assurance.